Health Professionals

This information sheet provides guidelines for clinicians’ use in monitoring patients with hepatitis C, who are being treated with peginterferon, ribavirin, and one of the protease inhibitors, either boceprevir or telaprevir. It includes a chart of the laboratory tests to be conducted at baseline and every two weeks to week 48 and six months post treatment as well as other tests to be done periodically while the patient is on antiviral therapy.

This information sheet explains to physicians how to interpret HCV test results. It uses a table format to list the HCV result, whether positive or negative, whether an anti-HCV supplemental test is needed, which supplemental test should be used, the interpretation of the supplemental test to determine whether the patient is HCV positive or negative, and the follow-up action to be taken if additional testing or evaluation is needed.

This card contains a flowchart, which outlines the various courses of action a physician should take after receiving a patient's anti-hepatitis C test results. The chart indicates no action after a negative HCV test and three different actions if the test is positive. It also advises when to stop the additional testing, when to continue, and when to have the patient medically evaluated for active infection and liver disease.

This report updates previous US Public Health Service recommendations for the management of health-care personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management have not changed, recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated.

This report updates US Public Health Service recommendations for the management of health-care personnel (HCP) who have occupational exposure to blood and/or other body fluids that might contain HIV. The principles of exposure management remain unchanged, but recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated.

This report updates CDC’s 2002 recommendations regarding screening tests to detect C. trachomatis and N. gonorrhoeae infections and provides new recommendations regarding optimal specimen types, the use of tests to detect rectal and oropharyngeal C. trachomatis and N. gonorrhoeae infections, and information regarding when supplemental testing is indicated.

This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines. Persistent infection with oncogenic HPV types can cause cervical cancer in women as well as other anogenital and oropharyngeal cancers in women and men. HPV also causes genital warts.